🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 71 of 173

  1. US 9962368

    Pro-neurogenic compounds

    Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9963699

    Methods for modulating C9ORF72 expression

    Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9962395

    Compositions and methods for maintaining cognitive function

    Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9957214

    Multifunctional radical quenchers

    Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9957569

    Recurrent gene fusions in prostate cancer

    Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9957324

    Anti-FLT-1 antibodies in treating duchenne muscular dystrophy

    Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9956172

    Implant compositions for the unidirectional delivery of therapeutic compounds to the brain

    Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9957259

    Selective HDAC1 and HDAC2 inhibitors

    Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9957305

    Anti-C. difficile toxin antibodies and associated methods

    Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9952216

    Brain-specific enhancers for cell-based therapy

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9951118

    Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9950037

    Enhancing progenitor cell numbers

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9951097

    Antibacterial compounds targeting isoprenoid biosynthesis

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9950044

    Treatment of pulmonary vascular remodeling with neprilysin

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9950053

    Use of the Salmonella SPP type III secretion proteins as a protective vaccination

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9950001

    Polynucleotides having bioreversible groups

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9950002

    Nanoparticles/theranostic vehicles

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9949928

    Biodegradable copolymers, systems including the copolymers, and methods of forming and using same

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9949927

    Bis-polymer lipid-peptide conjugates and nanoparticles thereof

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9949484

    Antimicrobial polyurethane materials and methods of forming and using same

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9944740

    Sugar containing, amphiphilic copolymers

    Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9944583

    Methods for ameliorating and preventing central nervous system inflammation

    Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9944652

    Deuterated amlexanox

    Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9945864

    Disease-associated antigens and methods of use thereof

    Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9937129

    Materials and methods for delivering compositions to selected tissues

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9938353

    Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9938500

    Hemangio-colony forming cells

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9937256

    Hydrogels for delivery of therapeutic compounds

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9937156

    Modulation of MRTF-A activity in pathologic fibrosis and wound healing

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9937141

    Carcinoma diagnosis and treatment, based on ODC1 genotype

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9938350

    Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9938589

    Compositions and methods for detecting human pegivirus 2 (HPgV-2)

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9938582

    Recurrent gene fusions in prostate cancer

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9932589

    EML4-ALK fusion gene

    Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9932383

    Cold- and menthol-sensitive receptor (CMR1)

    Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9931419

    Methods and compositions for liposomal formulation of antigens and uses thereof

    Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9932564

    Recombinant isfahan viral vectors

    Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9933434

    Therapeutic antibodies against ROR-1 protein and methods for use of same

    Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9931412

    Targeted theranostics

    Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9925180

    Compounds and anti-tumor NQO1 substrates

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9925156

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9926380

    Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9925223

    Methods for making and using antimicrobial peptides

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9926372

    Methods and compositions for modulation of blood-neural barrier

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9926602

    Recurrent gene fusions in prostate cancer

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9925270

    bFGF-polymer conjugates, methods for making the same and applications thereof

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9925237

    Polypeptide-polymer conjugates and methods of use thereof

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9925209

    Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.